Highlights Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Delayed Nasdaq Stockholm Other stock markets 04:01:00 2024-07-03 EDT			5-day change	1st Jan Change
4.58 ^SEK	-1.19%		-16.73%	-17.92%

06-20	Transcript : Egetis Therapeutics AB - Special Call
06-19	Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency	06-19	CI
Egetis Receives Promising Innovative Medicine Designation in the UK for Emcitate® for Treatment of MCt8 Deficiency	06-03	CI
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA	12-13	CI
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises	11-10	MT
Egetis Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Egetis Therapeutics AB Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency	23-10-27	CI
Egetis Therapeutics Seeks Marketing Authorization for Genetic Disorder Treatment in Europe	23-10-09	MT
Egetis Therapeutics AB Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency	23-10-09	CI
Egetis Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Egetis Therapeutics AB Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial	23-07-24	CI
Egetis Therapeutics AB Announces Site Activation in the Pivotal Retriact Trial for Emcitate	23-06-28	CI
Egetis Terminates Discussions Regarding Potential Acquisition	23-05-24	CI
Egetis Therapeutics Ends Talks for Potential Takeover	23-05-24	MT
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Egetis Comments on M&A Rumors	23-03-30	CI
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-22	CI
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Highlights

Filters